Biohaven Ltd. Cash and Restricted Cash
Biohaven Ltd. (BHVN) had Cash and Restricted Cash of $240.63 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $240.63M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $277.11M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $232.78M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $188.38M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $240.63M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $277.11M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $232.78M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $188.38M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $169.00M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $102.69M 10-Q · filed 2026-05-04 |
| 2024-12-31 | $102.54M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $88.02M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $242.32M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $186.93M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $252.12M 10-K · filed 2026-03-02 |
| 2023-09-30 | $125.99M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $201.95M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $190.59M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $242.60M 10-K · filed 2026-03-02 |
| 2022-09-30 | $51.42M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $23.96M 10-Q · filed 2023-07-31 |
| 2022-03-31 | $41.01M 10-Q · filed 2023-05-12 |
| 2021-12-31 | $77.06M 10-K · filed 2025-03-03 |
| 2021-09-30 | $362.70M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $83.51M 10-K · filed 2024-02-29 |
| 2019-12-31 | $9.92M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |